Generic Medicine Info
Indications and Dosage
Adult: 100 mg daily.
Renal Impairment
CrCl (mL/min) Dosage
<30 Contraindicated.
30-80   Reduce dose to 100 mg every other day.
Hepatic Impairment
Severe: Contraindicated.
May be taken with or without food.
Severe hepatic and renal (CrCl <30 mL/min) impairment. Pregnancy and lactation. Concurrent use w/ other fibrates.
Special Precautions
Patient w/ hypoalbuminaemia, nephrotic syndrome, hypothyroidism, alcohol abuse, history of hereditary muscular disorder, previous toxicity w/ other fibrates. Mild to moderate hepatic and renal impairment.
Adverse Reactions
Urticaria, rashes, pruritus, eczema; elevated CPK levels, myalgia, myositis; headache, vertigo; nausea, vomiting, anorexia, diarrhoea, dyspepsia, abdominal pain; thrombocytopenia. Rarely, photosensitivity, alopecia, rhabdomyolysis, dizziness, somnolence, impotence, cholestasis, cytolysis, pneumonitis, pulmonary fibrosis, fatigue, leukocytopenia, pancreatitis, peripheral neuropathy.
Patient Counseling Information
This drug may cause dizziness, somnolence, and fatigue, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor for renal function. Perform periodic LFT every 3 mth for the 1st yr of treatment. Monitor for serum creatine phosphokinase (CPK) levels of patients reporting unexplained muscle pain, tenderness, or weakness.
Symptom: Rhabdomyolysis. Management: Symptomatic and supportive treatment. Employ gastric lavage.
Drug Interactions
Increased risk of muscle effects esp rhabdomyolysis w/ HMG-CoA reductase inhibitors. Reduced absorption w/ cholestyramine and colestipol. May increase the effects of phenytoin, tolbutamide and other sulphonylurea derivatives, and coumarin-like anticoagulants. May potentiate the effect of warfarin.
Potentially Fatal: Increased risk of rhabdomyolysis and myoglobinuria w/ other fibrates.
Description: Ciprofibrate is a fibric acid derivative that has a marked hypolipidaemic action. It reduces both LDL and VLDL cholesterols, leading to reduced levels of triglycerides, while increasing the HDL cholesterol levels.
Absorption: Readily absorbed from the GI tract. Time to peak plasma concentration: W/in 1-4 hr.
Distribution: Plasma protein binding: Approx 98%.
Excretion: Via urine (as unchanged drug and glucuronide conjugates). Elimination half-life: Approx 38-86 hr.
Store below 25°C.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AB08 - ciprofibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.
Anon. Ciprofibrate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 21/07/2016.

Buckingham R (ed). Ciprofibrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 21/07/2016.

Joint Formulary Committee. Ciprofibrate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 21/07/2016.

Disclaimer: This information is independently developed by MIMS based on Ciprofibrate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in